Table 1.
Pooled CAPS-IV data from six phase 2 MAPS-sponsored studies of MDMA-assisted psychotherapy.
| Active group (MDMA 75–125 mg) N = 72 |
Control group (MDMA 0–40 mg) N = 31 |
|
|---|---|---|
| Change in CAPS-IV total scoresa, mean (SD) | −37.8 (29.29) | −11.6 (17.93) |
| Cohen’s d effect sizeb | 1.5 | 0.6 |
| Dropouts, n (%)c | 5 of 74 (6.8%) | 3 of 31 (9.7%) |
a
Change in CAPS-IV scores from baseline to the primary endpoint (1–2 months post 2–3 MDMA sessions).
b
Within-group Cohen’s d effect size calculated by dividing the change from baseline to primary endpoint by the standard deviation.
c
For the active group, 3 terminated early but completed an endpoint assessment and 2 terminated early with no endpoint assessments. For the control group, 3 terminated early but completed an endpoint assessment.